SCHEMBL268546

SCHEMBL268546

CC(O)CN(Cc1cccc(C(=O)Nc2cc3ccccc3cc2C(=O)NN)c1)CC(C)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
RECQL P46063 1/20 0.44
ACHE P22303 1/20 0.41
ITGA4 P13612 1/20 0.40
ITGB7 P26010 1/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.39
MITF O75030 1/20 0.39
GAA P10253 1/20 0.39
NCOA1 Q15788 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
PTGES O14684 1/20 0.38
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 2/20 0.37
ALDH1A1 P00352 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266202 0.89 KDM4E (0.46) TSHRRECQLACHEITGA4ITGB7
SCHEMBL268241 0.82 MGAM (0.44) MEN1KMT2AMAPTGAATDP1
SCHEMBL268242 0.82 MGAM (0.44) MEN1KMT2AMAPTGAATDP1
SCHEMBL269946 0.81 MAPT (0.49) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL267978 0.81 SLC34A2 (0.52) RECQLMEN1KMT2AMAPTGAA
SCHEMBL268117 0.81 SLC34A2 (0.41) TSHRRECQLMEN1KMT2AMAPT
SCHEMBL269945 0.81 MAPT (0.49) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL267977 0.81 SLC34A2 (0.52) RECQLMEN1KMT2AMAPTGAA
SCHEMBL268118 0.81 SLC34A2 (0.41) TSHRRECQLMEN1KMT2AMAPT
SCHEMBL266570 0.80 NPC1 (0.39) TSHRRECQLACHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 TSHR 729/4885RECQL 1619/4885ACHE 4048/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 TSHR 487/4885RECQL 1515/4885ACHE 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.